The city of Dallas, Texas, currently has 10 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/13/2024
Locations: Local Institution - 0073, Dallas, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/13/2024
Locations: Local Institution - 0024, Dallas, Texas +1 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059
Recruiting
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
06/12/2024
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: Baylor Scott and White Health - Advanced Lung Disease Specialists, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: Baylor Scott & White Center for Advanced Heart & Lung Disease, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: Baylor University Medical Center, Dallas, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: Baylor Scott & White Research Institute, Dallas, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/09/2024
Locations: University of Texas Southwestern, Dallas, Texas +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/09/2024
Locations: Univerity of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates